ReviewActa oncologica (Stockholm, Sweden)2025

How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?

Peeter KarihtalaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.